Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer
BN Cajiao Garcia, VD de Jager, CCHJ Epskamp-Kuijpers, AJ van der Wekken, SM Willems, LC van Kempen, E Schuuring · 2026
Read Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer by BN Cajiao Garcia, VD de Jager, CCHJ Epskamp-Kuijpers, AJ van der Wekken, SM Willems, LC van Kempen, E Schuuring (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13279202.txt.
Description
B. N. Cajiao Garcia and colleagues report a 2026 real world study of a rare gene join in lung cancer. The cancer is metastatic non small cell lung cancer, meaning it has spread. The join fuses the RET gene to a partner gene, and drugs can target it. Past claims put its rate at one to two percent of cases.
Care data from the Netherlands suggest the true rate is lower, in fact below one percent. Test method mattered a lot for sound counts. RNA based gene reads, which read the active gene script, beat an older spot test called FISH in accuracy. Test rates keep rising in Dutch care. Sound rates matter because they set who gets gene checks and who may gain from matched drugs.
Catalog record
| CREATOR | BN Cajiao Garcia, VD de Jager, CCHJ Epskamp-Kuijpers, AJ van der Wekken, SM Willems, LC van Kempen, E Schuuring |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27368 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |